Melanotan I

What Melanotan I is

Melanotan I — now universally referred to by its International Nonproprietary Name, afamelanotide — is a synthetic tridecapeptide and structural analogue of the endogenous peptide α-melanocyte-stimulating hormone (α-MSH) ^[1]. It belongs to the melanocortin peptide class and was designed to mimic the physiological effects of α-MSH by acting as a potent agonist at the melanocortin-1 receptor (MC1R), the key regulator of skin pigmentation ^[3]. The compound was first characterised in the early 1980s by researchers Victor J. Hruby and Mac E. Hadley at the University of Arizona, who synthesised and screened hundreds of molecular variants of α-MSH ^[7]. Their programme identified [Nle4, D-Phe7]-α-MSH — featuring a norleucine substitution at position 4 and a D-phenylalanine substitution at position 7 — as approximately 1,000 times more potent than natural α-MSH ^[7]. This heightened potency reflects greater metabolic stability and prolonged receptor engagement compared to the native hormone ^[8]. The peptide was originally named 'Melanotan' and later 'Melanotan I' to distinguish it from a structurally related but pharmacologically distinct compound; it is now formally known as afamelanotide and marketed as Scenesse® by Clinuvel Pharmaceuticals ^[1][6].

What it is being researched for

1. Erythropoietic Protoporphyria (EPP) and Phototoxicity Prevention

Erythropoietic protoporphyria is a rare, autosomal recessive metabolic disorder in which deficient ferrochelatase activity causes protoporphyrin IX to accumulate in red blood cells and skin tissue, where it absorbs visible light and generates reactive oxygen species, causing intense phototoxic pain ^[10]. Because afamelanotide stimulates MC1R-driven eumelanin production, it was hypothesised that pre-loading the skin with melanin would reduce phototoxic activation ^[10]. Two pivotal Phase III, multicentre, randomised, double-blind, placebo-controlled trials — conducted in both the EU and the US — evaluated this hypothesis ^[11]. The EU study demonstrated that treated patients experienced a median of 6.0 hours per day of pain-free direct sunlight exposure versus 0.8 hours in the placebo group (P=0.005), and the number of phototoxic reactions was significantly lower (77 vs. 146, P=0.04) ^[4]. The US study similarly showed a longer duration of pain-free time in the afamelanotide group compared with placebo ^[4]. Quality of life improved in both trials, and adverse events were mostly mild with no drug-related serious adverse events reported ^[5]. These results led to regulatory approval in the EU (2014), the US (2019), and Australia for the prevention of EPP phototoxicity ^[5].

2. Vitiligo and Repigmentation

Vitiligo is an autoimmune depigmentation disorder in which melanocytes are selectively destroyed, leaving patches of depigmented skin. Researchers have explored whether MC1R stimulation with afamelanotide, combined with narrowband UVB (NB-UVB) phototherapy, can accelerate repigmentation by promoting melanoblast differentiation, proliferation, and eumelanogenesis ^[2]. A pilot study in four patients with generalised vitiligo reported that afamelanotide induced faster and deeper repigmentation in each case, with follicular and confluent areas of repigmentation appearing within days to weeks after the initial implant ^[2]. A subsequent randomised, multicentre controlled trial (NCT01430195) published in JAMA Dermatology found that combination therapy — afamelanotide plus NB-UVB — produced clinically apparent, statistically superior, and faster repigmentation compared with NB-UVB monotherapy alone, with the response more noticeable in patients with darker Fitzpatrick skin phototypes (IV–VI) ^[8]. Additional studies in Asian patients with nonsegmental vitiligo have corroborated these findings, reporting statistically significant improvements in Vitiligo Area Scoring Index scores in the combination group ^[6].

3. Solar Urticaria

Solar urticaria is a rare form of chronic inducible urticaria characterised by itch, weal and flare reactions within minutes of sunlight exposure, with an action spectrum typically spanning long-wavelength UVA and visible light ^[3]. Eumelanin's ability to absorb and scatter light across a broad wavelength range makes it a rational candidate for modulating this condition ^[12]. A Phase II pilot study (NCT00859534) examining afamelanotide in solar urticaria showed significant increases in melanin density and pain-free light exposure time ^[9]. A study published in the British Journal of Dermatology reported that melanisation following afamelanotide treatment was accompanied by reduction in the solar urticarial response across a broad spectrum of wavelengths, with the authors noting that further study under ambient summer conditions was warranted ^[7]. The broader evidence base for this indication remains at early-phase level, and solar urticaria has not yet reached the approval threshold achieved for EPP ^[1].

4. Polymorphic Light Eruption (PLE)

Polymorphic light eruption (PLE) is the most common photodermatosis, presenting as an itchy, erythematous rash following UV exposure in susceptible individuals. The rationale for studying afamelanotide in PLE mirrors that for EPP and solar urticaria: by inducing melanisation of the skin, the peptide may provide photoprotection and reduce eruption severity ^[6]. Afamelanotide has been reported to reduce symptoms in PLE across Phase II studies, and a completed Phase III randomised, placebo-controlled trial (NCT04704713) evaluated its safety and efficacy specifically in PLE patients ^[7]. A 2021 pharmacokinetics review noted that promising therapeutic results have been published in PLE and highlighted that afamelanotide's photoprotective mechanism increases melanin levels without requiring additional UV exposure — a potential advantage over photohardening approaches ^[1]. Evidence from this indication remains more limited than for EPP, and ongoing regulatory review continues ^[1].

5. DNA Repair Enhancement and Genomic Stability

Beyond its pigmentation effects, MC1R activation by afamelanotide has been shown to enhance nucleotide excision repair (NER) of UV-induced DNA photoproducts, including cyclobutane pyrimidine dimers and 6-4 photoproducts ^[5]. Research published in the International Journal of Molecular Sciences described how MC1R activation raises intracellular cyclic AMP (cAMP), which engages both MITF-driven melanogenesis and separate cAMP-mediated DNA repair pathways ^[3]. A study published in Frontiers in Genetics documented that human melanocytes expressing functional MC1R respond to α-MSH treatment with increased efficiency of repair of UV-induced DNA photoproducts and reduced hydrogen peroxide generation ^[10]. An important finding is that this DNA repair function appears to operate independently of pigmentation in keratinocytes via an XPA-dependent mechanism, suggesting photoprotective actions in non-melanocyte skin cells as well ^[5]. Afamelanotide has also been investigated as a potential DNA repair-enhancing agent in xeroderma pigmentosum, a condition characterised by deficient UV-damage repair ^[5]. These findings suggest that afamelanotide's photoprotective profile extends beyond simple UV absorption by melanin.

6. Skin Photoprotection in Photosensitive Populations

Independent of specific disease states, researchers have examined whether afamelanotide can provide a quantifiable photoprotective benefit in healthy volunteers or populations with inherently low baseline eumelanin — such as those carrying MC1R variant alleles associated with fair skin and red hair ^[7]. A Phase II clinical trial conducted in Australia found that afamelanotide effectively increased melanin content in individuals with MC1R variant alleles — precisely the population most in need of photoprotection ^[7]. A study published in the British Journal of Dermatology examined the minimum erythema dose (MED) in healthy volunteers with Fitzpatrick skin phototypes II–III and found that afamelanotide reduced the ultraviolet radiation erythemal response even soon after application, suggesting early-onset photoprotective activity ^[8]. Human volunteer research has also confirmed that afamelanotide induces visible skin darkening even without UV co-exposure, distinguishing it from conventional tanning achieved through UV irradiation alone ^[5].

7. Antioxidant and Anti-inflammatory Properties

Afamelanotide's MC1R agonism triggers downstream effects that go beyond melanogenesis to include the induction of antioxidant enzymes and modulation of inflammatory pathways ^[1][3]. When MC1R signalling is promoted by afamelanotide, research has documented enhanced antioxidant activity, DNA repair, and production of immunomodulatory proteins including interleukin-10 ^[1]. Specifically, MC1R activation has been shown to upregulate antioxidant enzymes such as catalase, hemeoxygenase-1, γ-glutamylcysteine synthase, and glutathione-S-transferase, reducing oxidative burden in UV-irradiated melanocytes ^[10]. Eumelanin itself contributes to this effect by acting as a free-radical scavenger and a neutral-density filter that reduces all wavelengths of light approximately equally, providing wavelength-independent photoprotection ^[4]. The anti-inflammatory component of MC1R activation may also be relevant in photodermatoses where immune dysregulation contributes to skin damage, though this area of research is less advanced and primarily supported by cell-culture and small clinical data ^[1].

How it is thought to work

Afamelanotide acts as a potent and selective agonist of the melanocortin-1 receptor (MC1R), a G-protein-coupled receptor (GPCR) expressed predominantly on melanocytes in the skin ^[3]. Upon binding MC1R, afamelanotide activates adenylyl cyclase, raising intracellular levels of cyclic adenosine monophosphate (cAMP) ^[3]. Elevated cAMP activates the cAMP-response element-binding protein (CREB) via protein kinase A (PKA) and subsequently upregulates microphthalmia-associated transcription factor (MITF), which drives the transcription of key melanogenic enzymes including tyrosinase, TRP-1, and TRP-2 ^[5]. The net result is a marked increase in the synthesis of eumelanin — the brown-black, photoprotective pigment — rather than pheomelanin, the reddish-yellow pigment that can itself generate reactive oxygen species upon UV exposure ^[5]. This MC1R selectivity distinguishes afamelanotide pharmacologically from Melanotan II, which is a non-selective melanocortin receptor agonist ^[3].

Beyond melanogenesis, the same cAMP signalling cascade activated by afamelanotide engages parallel pathways that enhance nucleotide excision repair (NER) of UV-induced DNA photoproducts through upregulation of XPA and related repair factors ^[5]. MC1R activation also transactivates transcription factors including p53, Nrf2, and MITF, contributing to antioxidant defences, reduced hydrogen peroxide generation, and increased expression of antioxidant enzymes ^[9]. Afamelanotide has been shown to promote the production of immunomodulatory proteins including interleukin-10, suggesting an anti-inflammatory dimension to its activity that may be relevant in photodermatoses characterised by immune dysregulation ^[1]. Collectively, these mechanisms produce a multi-layered photoprotective response: physical UV attenuation by eumelanin, molecular scavenging of reactive oxygen species, and enhanced genomic repair capacity in UV-exposed cells ^[4].

Where the evidence stands

The strongest clinical evidence for afamelanotide comes from two pivotal Phase III, multicentre, randomised, double-blind, placebo-controlled trials in erythropoietic protoporphyria, the results of which were published in the New England Journal of Medicine in 2015 ^[4]. These trials, enrolling patients in both the EU and the US, demonstrated statistically significant increases in pain-free direct sunlight exposure and improved quality of life in treated patients relative to placebo, with a generally mild adverse event profile ^[4][5]. A long-term observational study in 115 EPP patients further corroborated these findings, reporting sustained increases in phototoxic burn tolerance time over multi-year follow-up ^[1]. In vitiligo, a randomised multicentre controlled trial published in JAMA Dermatology found that combination therapy with afamelanotide plus NB-UVB produced superior and faster repigmentation compared with NB-UVB monotherapy, with the response particularly notable in patients with darker skin phototypes ^[8]. Randomised controlled trial evidence also exists for polymorphic light eruption, and Phase II data support a signal of benefit in solar urticaria ^[6][7].

Despite this relatively robust clinical base compared with most peptide research compounds, several limitations and evidence gaps remain. Many indications beyond EPP — including solar urticaria, Hailey-Hailey disease, and acne — are supported only by smaller, early-phase, or uncontrolled studies, and no regulatory approval has been granted for these conditions ^[6]. The vitiligo evidence, while promising, was generated in specific patient populations (darker Fitzpatrick skin phototypes) and may not generalise broadly ^[8]. Mechanistic evidence regarding DNA repair enhancement and anti-inflammatory effects is largely derived from cell-culture and animal studies, with only limited direct human evidence — a gap acknowledged in published reviews ^[3][10]. Afamelanotide does not address the underlying ferrochelatase deficiency in EPP and is explicitly not a cure for the disease ^[3]. Ongoing research is exploring afamelanotide in additional conditions such as variegate porphyria and xeroderma pigmentosum, but those programmes remain at early or intermediate phases ^[1].

Frequently asked questions

What is Melanotan I and is it the same as Melanotan II?

Melanotan I is the original research name for afamelanotide, a synthetic peptide analogue of alpha-MSH that selectively activates the MC1R receptor to stimulate eumelanin production and photoprotection. Melanotan II is a structurally related but pharmacologically distinct compound that is non-selective across multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), producing a broader range of effects. The two peptides are not interchangeable and have very different evidence profiles and regulatory statuses.

Is Melanotan I (afamelanotide) approved by a regulatory agency?

Yes. Afamelanotide is approved by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration (TGA). In each jurisdiction, the approved indication is the prevention of phototoxicity in adults with erythropoietic protoporphyria. It is marketed under the brand name Scenesse® and is available only as a prescription-only medicine through licensed prescribers.

What conditions is afamelanotide being researched for beyond EPP?

Beyond its approved use in erythropoietic protoporphyria, afamelanotide has been studied in clinical trials for vitiligo, polymorphic light eruption, solar urticaria, Hailey-Hailey disease, acne vulgaris, and is being investigated for xeroderma pigmentosum and variegate porphyria. The strength of the evidence varies widely across these conditions, with the most robust data available for vitiligo and polymorphic light eruption.

How does Melanotan I protect the skin from UV damage?

Afamelanotide stimulates the melanocortin-1 receptor (MC1R) on melanocytes, triggering a cAMP signalling cascade that upregulates eumelanin synthesis. Eumelanin acts as a natural, wavelength-independent UV and visible-light filter that absorbs and scatters photons and scavenges free radicals. Separately, MC1R activation also enhances nucleotide excision repair of UV-induced DNA photoproducts and upregulates antioxidant enzymes, providing photoprotection beyond simple pigmentation.

What did the 2015 New England Journal of Medicine study find?

The landmark 2015 NEJM publication reported results from two Phase III randomised, double-blind, placebo-controlled trials in EPP patients conducted in the EU and the US. The EU study found a median of 6.0 hours of pain-free daily sunlight exposure in the treatment group versus 0.8 hours in the placebo group, and the number of phototoxic reactions was significantly reduced. Both trials reported improved quality of life with an acceptable adverse event profile.

What are the known side effects of afamelanotide in research studies?

Clinical trials consistently report that afamelanotide is generally well tolerated, with diffuse hyperpigmentation experienced by almost all patients as an expected pharmacological consequence of eumelanin stimulation. Commonly reported adverse reactions in Phase III trials included headache and implant-site reactions. No drug-related serious adverse events were reported in the pivotal EPP trials. Hyperpigmentation of oral soft tissues has also been documented in case reports.

What is the difference between eumelanin and pheomelanin, and why does it matter for research?

Eumelanin is the brown-black form of melanin that absorbs UV and visible light across a broad wavelength spectrum, scavenges free radicals, and acts as a genuine photoprotective agent in skin. Pheomelanin is the reddish-yellow form predominant in fair-skinned individuals with certain MC1R variants, and it can generate reactive oxygen species upon UV exposure rather than quenching them. Afamelanotide preferentially promotes eumelanin over pheomelanin, which is central to its photoprotective research rationale.

Has afamelanotide been studied in vitiligo patients?

Yes. A randomised multicentre trial published in JAMA Dermatology (2015) evaluated combination therapy of afamelanotide with narrowband UVB phototherapy versus NB-UVB monotherapy in patients with nonsegmental vitiligo. The combination arm produced statistically significant and faster repigmentation, particularly in patients with Fitzpatrick skin phototypes IV–VI. Earlier pilot data and subsequent studies in Asian patients have corroborated these findings, though vitiligo remains an investigational use without regulatory approval.

What receptor does Melanotan I bind to and why is MC1R selectivity important?

Melanotan I (afamelanotide) binds preferentially and with high affinity to the melanocortin-1 receptor (MC1R), with minimal activity at other melanocortin receptor subtypes (MC3R, MC4R, MC5R). This selectivity means its effects are largely localised to melanocyte activation and eumelanin synthesis, without the broader systemic effects associated with non-selective melanocortin agonists. MC1R selectivity is considered the defining pharmacological feature that underpins afamelanotide's targeted photoprotective profile.

Can Melanotan I prevent melanoma?

This is an area of active preclinical investigation but has not been established in humans. Laboratory and animal research suggests that sustained MC1R activation enhances DNA repair and antioxidant defences in melanocytes, which could theoretically reduce UV-induced mutagenic burden. However, researchers and regulators explicitly caution that MC1R activation does not prevent melanoma, and regular dermatological examination remains critical for individuals at elevated risk. No clinical trials have yet demonstrated a preventive effect on melanoma incidence in humans.

Glossary

α-Melanocyte-Stimulating Hormone (α-MSH)

An endogenous peptide hormone produced by the pituitary gland that acts on MC1R receptors in the skin to regulate melanin synthesis and pigmentation; afamelanotide is a synthetic, more potent analogue of this hormone.

Melanocortin-1 Receptor (MC1R)

A G-protein-coupled receptor expressed primarily on melanocytes that, when activated, triggers cAMP signalling cascades leading to eumelanin production, DNA repair enhancement, and antioxidant responses.

Eumelanin

The brown-black, photoprotective form of melanin synthesised preferentially when MC1R is activated; it absorbs UV and visible light across a broad wavelength range and scavenges reactive oxygen species.

Erythropoietic Protoporphyria (EPP)

A rare autosomal recessive metabolic disorder caused by deficient ferrochelatase activity, leading to accumulation of protoporphyrin IX in skin and severe phototoxic pain upon light exposure.

Eumelanogenesis

The biochemical pathway through which melanocytes synthesise eumelanin, regulated primarily by tyrosinase and related enzymes under the transcriptional control of MITF downstream of MC1R activation.

Nucleotide Excision Repair (NER)

A DNA repair mechanism that removes bulky UV-induced DNA lesions — including cyclobutane pyrimidine dimers and 6-4 photoproducts — and is upregulated by MC1R/cAMP signalling in melanocytes and keratinocytes.

MITF (Microphthalmia-Associated Transcription Factor)

A master transcription factor in melanocytes that is upregulated downstream of cAMP/PKA signalling and controls the expression of melanogenic enzymes including tyrosinase, TRP-1, and TRP-2.

Polymorphic Light Eruption (PLE)

The most common photodermatosis, characterised by an itchy, erythematous rash appearing on sun-exposed skin in susceptible individuals, often in spring or early summer.

References

1. Afamelanotide — DermNet NZ — DermNet NZ (peer-reviewed dermatology reference)
2. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo — JAMA Dermatology / PubMed (PMID 23407924)
3. Afamelanotide for Erythropoietic Protoporphyria — NEJM 2015 (Phase III Trials) — New England Journal of Medicine — DOI: 10.1056/NEJMoa1411481
4. Afamelanotide for Erythropoietic Protoporphyria — NEJM 2015 (Phase III Trials) — New England Journal of Medicine — DOI: 10.1056/NEJMoa1411481
5. Afamelanotide: A Review in Erythropoietic Protoporphyria — Drugs / PubMed (PMID 26979527)
6. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial — JAMA Dermatology / PubMed (PMID 25230094)
7. Systemic photoprotection in solar urticaria with α-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH — British Journal of Dermatology / PubMed (PMID 20969564)
8. PD03: Afamelanotide reduces the ultraviolet radiation erythemal response soon after application in healthy volunteers with skin phototypes II–III — British Journal of Dermatology — DOI: 10.1093/bjd/ljad113.341
9. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders — Clinical Pharmacokinetics — DOI: 10.1007/s40262-016-0501-5
10. MC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair — International Journal of Molecular Sciences — DOI: 10.3390/ijms19092667